The polymorphism rs763780 in the IL-17F gene is associated with response to biological drugs in patients with psoriasis

Pharmacogenomics. 2015;16(15):1723-31. doi: 10.2217/pgs.15.107. Epub 2015 Sep 29.

Abstract

Psoriasis improves when IL-17 is blocked. Anti-TNF drugs reduce the IL-17 signaling pathway, and anti-IL-17 drugs are being developed to treat moderate-to-severe psoriasis. We analyzed three SNPs in IL-17A (rs2275913 and rs10484879) and IL-17F (rs763780) to look for an association with psoriasis and/or with response to anti-TNF drugs or ustekinumab. We included 197 healthy controls and 194 patients with moderate-to-severe psoriasis. The results of the univariate analysis showed an association between rs10484879 and psoriasis, although this relationship disappeared after adjustment for HLA-C (rs12191877). We also found an association between rs763780 (IL-17F) and response to ustekinumab (n = 70) and infliximab (n = 37) at 3 and 6 months and an association between rs763780 and the response to adalimumab at 6 months (n = 67).

Keywords: IL-17; adalimumab; etanercept; infliximab; pharmacogenetics; psoriasis; rs10484879; rs2275913; rs763780; ustekinumab.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Asian People
  • Female
  • Genetic Predisposition to Disease
  • Genotype
  • HLA-C Antigens / genetics
  • Humans
  • Infliximab / therapeutic use
  • Interleukin-17 / genetics*
  • Male
  • Pharmacogenetics
  • Polymorphism, Genetic / genetics*
  • Polymorphism, Single Nucleotide
  • Psoriasis / drug therapy*
  • Psoriasis / genetics*
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors
  • Ustekinumab / therapeutic use
  • Young Adult

Substances

  • HLA-C Antigens
  • IL17F protein, human
  • Interleukin-17
  • Tumor Necrosis Factor-alpha
  • Infliximab
  • Ustekinumab